Improved Outlook for Crohn’s disease due to New Medical TherapiesAccording to a recent study by the Mayo Clinic, administration of infliximab (Remicade) alone or in a combination with azathioprine may prove to be the most effective form of treatment than azathioprine alone for curing moderate to severe Crohn’s disease in patients.

Crohn’s disease is an inflammatory ailment of the human gastrointestinal tract that is believed to affect as much as 500,000 people in the United States alone. No definite cure has yet been discovered for this ailment.

In the past, patients suffering from this disease have been treated sequentially with some form of steroids followed by azathioprine and thereafter by monoclonal anti-bodies like infliximab.

However, infliximab-based medical strategies to cure Crohn’s disease are far more effective than treatment with azathioprine as per William Sandborn, M.D., the lead author and a gastroenterologist at Mayo Clinic.

This study is expected to create a new paradigm besides offering new, safer opportunities to patients suffering from Crohn’s disease when it comes to improving quality of life.